Analysts Set Geron Co. (NASDAQ:GERN) Price Target at $7.25

Geron Co. (NASDAQ:GERN) has earned an average rating of “Buy” from the eleven ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.25.

GERN has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Geron in a research report on Tuesday, December 10th. Scotiabank assumed coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. Barclays upgraded shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Needham & Company LLC upped their target price on shares of Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th.

Geron Stock Down 1.7 %

Shares of NASDAQ:GERN opened at $2.96 on Tuesday. The firm has a 50 day simple moving average of $3.57 and a 200-day simple moving average of $4.11. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.79 billion, a PE ratio of -9.25 and a beta of 0.55.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same period in the previous year, the company earned ($0.08) earnings per share. Geron’s quarterly revenue was up 17138.4% compared to the same quarter last year. On average, equities analysts predict that Geron will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Geron

A number of hedge funds have recently added to or reduced their stakes in the company. Readystate Asset Management LP purchased a new position in shares of Geron during the 3rd quarter worth approximately $58,000. Rovin Capital UT ADV purchased a new position in Geron in the third quarter worth $62,000. Empowered Funds LLC acquired a new stake in Geron in the third quarter valued at $67,000. Inspire Advisors LLC purchased a new stake in shares of Geron during the 3rd quarter worth $68,000. Finally, Monterey Private Wealth Inc. acquired a new position in shares of Geron during the 4th quarter worth $63,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.